Yahoo Web Search

  1. Mallinckrodt Enrolls First Patient in Liver Disease Study

    Zacks via Yahoo FinanceAug 13 15:53 PM

    Mallinckrodt plc MNK announced that it has enrolled the first patient in a phase IIa study on its investigational oral drug MNK-6106 (L-ornithine phenylacetate) for treating hepatic ...

  2. Shares of Mallinckrodt PLC (NYSE: MNK) traded higher following a clinical readout from the company. Mallinckrodt announced positive top-line results from the pivotal Phase ...

  3. Investors in Mallinckrodt plc MNK need to pay close attention to the stock based on moves in the options market lately. Options with high levels of implied volatility suggest that ...

  4. (NASDAQ: GHSI)(announced $5.2 million common stock offering) Haemonetics Corporation (NYSE: HAE) Hemispherx BioPharma, Inc (NYSE: HEB) Mallinckrodt PLC (NYSE: MNK) Meridian Bioscience ...

  5. Novocure Ltd (NASDAQ: NVCR) AbbVie Inc (NYSE: ABBV) Acer Therapeutics Inc (NASDAQ: ACER) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) Aldeyra ...

  6. (IPOed July 1) Acer Therapeutics Inc (NASDAQ: ACER) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Adial Pharmaceuticals Inc (NASDAQ: ADIL) ...

  7. Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...